Previous Article | Next Article 
Infection and Immunity, June 2000, p. 3642-3650, Vol. 68, No. 6
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Antibody Interactions with the Capsule of
Cryptococcus neoformans
Marta
Feldmesser,1
Johanna
Rivera,2
Yvonne
Kress,3
Thomas R.
Kozel,4 and
Arturo
Casadevall1,2,*
Division of Infectious Diseases, Department of
Medicine,1 and Departments of
Microbiology and Immunology2 and
Pathology,3 Albert Einstein College of
Medicine, Bronx, New York, and Department of
Microbiology, University of Nevada School of Medicine, Reno,
Nevada4
Received 2 December 1999/Returned for modification 25 January
2000/Accepted 23 February 2000
 |
ABSTRACT |
Monoclonal antibodies to the encapsulated fungus Cryptococcus
neoformans produce different immunofluorescence (IF) patterns after binding to the polysaccharide capsule. To explore the
relationship between the IF pattern and the location of antibody
binding, two immunoglobulin M (IgM) monoclonal antibodies (MAbs) (12A1
and 13F1) that differ in protective efficacy and IF pattern and one protective IgG1 MAb (2H1) were studied by IF and electron microscopy (EM). Fixing C. neoformans cells in lung tissue for EM
resulted in significantly better preservation of the capsule than
fixing yeast cells in suspension. The localization of MAbs 12A1 and
13F1 by immunogold EM differed depending on whether the MAb was bound to cells in cut tissue sections embedded in plastic or to cells in
solution. In cut tissue sections, MAbs 12A1 and 13F1 bound throughout
the capsule, whereas in solution both MAbs bound near the capsule
surface. To investigate whether antibody binding to the C. neoformans capsule affected the binding of other primary or
secondary reagents, various combinations of MAbs 12A1, 13F1, and 2H1
were studied by direct and indirect IF. The IF pattern and location of
binding for MAbs 12A1, 13F1, and 2H1 varied depending on the presence
of other capsule-binding MAbs and the method of detection. The results
show that (i) binding of MAbs to the C. neoformans
polysaccharide capsule can modify the binding of subsequent primary or
secondary antibodies; (ii) the IgM MAbs bind primarily to the outer
capsule regions despite the occurrence of their epitopes throughout the
capsule; and (iii) MAb 2H1 staining of newly formed buds is reduced,
suggesting quantitative or qualitative differences in bud capsule.
 |
INTRODUCTION |
Polysaccharide capsules are
associated with virulence for many pathogens. Studies in the early 20th
century found that antibody binding to bacterial polysaccharide
capsules promotes phagocytosis, complement activation, agglutination,
and capsular reactions (reviewed in reference 2).
Although much is known about the interaction of antibody molecules with
polysaccharide antigens in the fluid phase, relatively little
information is available regarding antibody binding to intact microbial
capsules. Cryptococcus neoformans is remarkable among the
medically important fungi because it has a large polysaccharide capsule
that is composed primarily of glucuronoxylomannan (GXM) (6).
Dozens of well-characterized monoclonal antibodies (MAbs) that bind to
the GXM component of the cryptococcal capsule are available (3,
11, 12, 27, 34). The combination of a large polysaccharide
capsule and the availability of MAb reagents makes this fungus a
particularly powerful system to study antibody-capsule interactions.
Like the case for other encapsulated pathogens, the complement system
and humoral immunity contribute to protection against C. neoformans infection (reviewed in references 15, 18, 26,
and 38).
The protective efficacy of antibodies against C. neoformans
depends on the antibody specificity and isotype (reviewed in references 15, 26, and 38). MAbs to C. neoformans can mediate many biological functions, including
protection in mice (reviewed in reference 38),
opsonization (24, 32), complement activation (19), and lymphocyte proliferation and modification of
cytokine release by mononuclear cells (33, 39). The
immunoglobulin M (IgM) MAbs 12A1 and 13F1 differ in epitope specificity
and protective efficacy (23). These two IgM MAbs are
believed to originate from a single pre-B cell, but their variable
regions differ by several amino acid substitutions as a result of
somatic mutations (23). MAb 12A1 is protective and binds to
serotype A, D, and AD strains in an annular indirect immunofluorescence
(IF) pattern (7, 8). In contrast, MAb 13F1 binds to A and D
strains in annular and punctate patterns, respectively (7,
8). Annular IF patterns have been correlated with the ability of
the MAb to mediate protection for a small number of C. neoformans strains (25). Punctate binding by MAb 13F1
has not been associated with protective efficacy (23, 25).
In vitro assays have shown that punctate binding is associated with
poor opsonic activity, whereas annular binding is associated with
opsonization and killing of C. neoformans by murine
macrophages (8). However, the nature of the antigen-antibody
interactions responsible for the annular and punctate binding patterns
by IF is not understood.
To understand the function of antibodies against encapsulated
pathogens, it is important to determine how they interact with microbial capsules. However, a persistent problem in this field is that
microbial capsules are fragile and easily disrupted by sample
preparation for ultrastructural studies. In this study, we explored the
binding of MAbs to the C. neoformans capsular polysaccharide
using electron microscopy (EM) and IF. EM studies took advantage of the
serendipitous observation that C. neoformans capsules are
well preserved when the fungus is studied after instillation into mouse
lung tissue. The results indicate that different binding patterns
reflect differences in the location of antibody binding to the
polysaccharide capsule and that the binding of one antibody to the
capsule can modify the binding of subsequent antibodies.
(The data in this paper are from a thesis to be submitted by J.R. in
partial fulfillment of the requirements for a Ph.D. from the Sue
Golding Graduate Division of Medical Science, Albert Einstein College
of Medicine, Yeshiva University, Bronx, N.Y.)
 |
MATERIALS AND METHODS |
C. neoformans.
American Type Culture Collection strain
24067 (serotype D) was used for all experiments. This strain was
selected for study because it produces annular and punctate IF patterns
after MAb 12A1 and 13F1 binding, respectively (23). Serotype
D strains are common among clinical isolates in Europe (10).
C. neoformans cells were grown in Sabouraud dextrose broth
for 24 to 48 h at 30°C, collected by centrifugation, washed with
0.02 M phosphate-buffered saline (PBS), pH 7.2, and used in antibody
binding experiments. The average capsule size of strain 24067 is
2.8 ± 1.4 µm in vitro or 20.0 ± 6.1 µm in vivo
(29).
MAbs.
The MAbs 13F1 (IgM), 12A1 (IgM), and 2H1 (IgG1) have
been described elsewhere (4, 22, 23). MAb 2H1 has
serological characteristics similar to those of MAb 12A1 and probably
binds to the same antigenic determinant (23). Hybridoma
supernatant fluids were concentrated to yield solutions with high MAb
concentration. Ascites fluid obtained from BALB/c mice injected with
hybridoma cells was also used as a source of hybridoma protein. MAb 2H1 (IgG1) was purified from ascites fluid using protein G affinity chromatography (Pierce, Rockford, Ill.) as instructed by the
manufacturer. MAbs 12A1 and 13F1 (IgM) were purified from ascites fluid
using immobilized mannan-binding protein (Pierce) as instructed by the manufacturer. The concentration of MAb was determined by enzyme-linked immunosorbent assay relative to isotype-matched standards of known concentration. Purified MAb 2H1 was labeled with Alexa 546, and MAbs
12A1 and 13F1 were labeled with Alexa 488 (Molecular Probes, Eugene,
Oreg.), as instructed by the manufacturer. Alexa 546 is similar to
rhodamine and has absorption and fluorescence emission maxima of ~558
and 573 nm, respectively. Alexa 488 is similar to fluorescein and has
absorption and fluorescence emission maxima of ~494 and 519 nm, respectively.
Mice.
A/JCr mice were used for infection experiments to
investigate the expression of the 12A1 and 13F1 epitopes in vivo. That
mouse strain was used because it is very susceptible to infection
(28) and the higher tissue burdens facilitated
identification of yeast cells in organ homogenates. C57BL/6 mice were
used for all experiments where C. neoformans was inoculated
intratracheally to preserve the capsule for EM. Mice were obtained from
the National Cancer Institute (Bethesda, Md.) and infected
intratracheally as described elsewhere (14). Briefly, mice
were anesthetized with 65 mg of sodium pentobarbital per kg of body
weight and inoculated with 106 C. neoformans
cells into the trachea following exposure via a midline neck incision
using a 26-gauge needle attached to a tuberculin syringe. At either 5 min, 2 h, or 14 days after infection, mice were killed by cervical
dislocation and the lungs were removed.
Immunogold labeling.
The lungs were fixed overnight in
Trump's EM fixative (1% glutaraldehyde-4% paraformaldehyde in PBS),
incubated in 1% osmium for 1 h, dehydrated, and embedded in
araldite-Epon. Ultrathin sections were placed on copper or nickel grids
and imaged using a JEOL 100CX electron microscope (JEOL, Ltd., Tokyo,
Japan). The same protocol was used for experiments to study epitope
distribution in yeast cells during infection, except that lungs were
removed at day 14 of infection. For labeling of tissue postfixation,
tissue on nickel grids from infected mice was incubated in 3%
H2O2 for 10 min, washed in PBS, and etched for
10 min in a saturated solution of sodium periodate. Etching was done
only for sections stained postembedding, and this step did not destroy
the GXM, as evidenced by strong immunogold labeling in etched samples
with the three MAbs. Sections were blocked by incubation in 2% goat
serum and incubated in MAb 12A1, 13F1, or 2H1 or in murine IgM or IgG
as a control at a concentration of 5 µg/ml overnight at 4°C. The murine antibody controls had no reactivity for the yeast or the surrounding murine lung tissue. After washing, sections were incubated in biotin-conjugated goat anti-mouse IgM (GAM-IgM) (for 12A1 or 13F1)
or GAM-IgG (for 2H1) (Southern Biotechnology Associates, Inc.,
Birmingham, Ala.) (each at 5 µg/ml) for 1 h at room temperature, washed, and incubated in streptavidin conjugated to 10-nm gold (Goldmark Biologicals, Philipsburg, Pa.) at a dilution of 1:30 for
2 h at room temperature. After washing, the grids were fixed in
2% glutaraldehyde.
For labeling of C. neoformans cells prior to inoculation
into mice, 2 × 108 washed yeast cells were incubated
in either 12A1, 13F1, or murine IgM (10 µg/ml) for 1 h at room
temperature and washed. Additional samples were also incubated for
2 h at room temperature in GAM-IgG or GAM-IgM conjugated to 10-nm
gold diluted 1:30. One mouse each was inoculated with one of these six
samples. In an additional experiment, immunogold labeling was performed
as above, except that the primary antibodies were used at a
concentration of 200 µg/ml. Grids from this latter experiment were
also incubated after embedding with gold-conjugated secondary antibody.
IF of yeast cells from organ homogenates.
Brain and lung
tissue were ground by mechanical disruption through a mesh strainer in
10 ml of PBS. Aliquots of the organ homogenate were washed twice with
PBS. MAb 12A1 or 13F1 was added to the homogenate at a concentration of
50 µg/ml in blocking solution (1% bovine serum albumin, 0.5% horse
serum) and incubated at 37°C for 30 min. Cells were then washed twice
with blocking solution, incubated with 10 µg of fluorescein
isothiocynate (FITC)-labeled GAM-IgM (Southern Biotechnology) per ml
for 30 min at 37°C in the dark, washed again with blocking solution,
and suspended in mounting medium (0.1 M n-propyl gallate in
PBS [Sigma, St. Louis, Mo.]). Twenty microliters of cell suspension
was placed on a slide with 20 µl of 1% diethanol-PBS (Ciba-Geigy,
Greensboro, N.C.), which stains the fungal cell wall (20).
Coverslips were mounted, and a small drop of India ink (Difco
Laboratories, Detroit, Mich.) was added. The slides were then viewed
with an Olympus IX 70 microscope (Olympus America, Melville, N.Y.) with
60× numerical aperture 1.4 optics equipped with standard FITC and
4',6-diamidino-2-phenylindole (DAPI) filters. Image reconstruction was
done using Adobe Photoshop version 3 as described below.
In vitro IF studies.
Slides were coated with
poly-L-lysine (0.1 mg/ml; Sigma), and 106 yeast
cells were allowed to air dry on slides so that organisms adhered.
Previous studies have shown that the IF patterns produced by MAb
binding to C. neoformans are the same regardless of whether the antibody is bound to yeast cells in solution or after attachment to
glass slides (8, 25). MAb 2H1, 12A1, or 13F1 was added at a
concentration of 200 µg/ml in blocking solution. FITC-labeled GAM-IgM
(F-GAM-IgM), F-GAM-IgG1, tetramethylrhodamine isothiocyanate (TRITC)-labeled GAM-IgM (R-GAM-IgM), and R-GAM-IgG1 (all from Southern
Biotechnology) were added at a concentration of 10 µg/ml after
application of each unconjugated MAb. The binding pattern of each of
the three MAbs was studied (i) individually using primary unconjugated
MAbs followed by FITC- or TRITC-labeled GAM reagents, (ii) with the
directly labeled MAbs, or (iii) in various combinations as listed in
Table 1. All incubations were done at
37°C for 30 min, and slides were washed three times with PBS between
application of reagents. Slides were washed again with PBS, 30 µl of
mounting medium (0.1 M n-propyl gallate-50% glycerol in
PBS) was added, and coverslips were placed. The slides were then viewed
as described above. Fluorescent images were recorded with narrow band
filter sets to ensure that there was no cross talk or spillover from one filter set to the others. Grey scale images were merged. This method is equivalent to multiple exposure photography but with the
benefits of wider linear response and wider dynamic range, guaranteed
optical separation of filters, and the convenience of digital storage.
Spatial registration of images with different filter sets was
calibrated with 0.2-µm-diameter beads as part of the standard quality
control at the microscope facility. Images were recorded in black and
white. Color corresponding to the filter wavelength was subsequently
added back during image reconstruction to reflect the actual color
observed.
 |
RESULTS |
Preservation of capsule in mouse lungs.
While studying aspects
of C. neoformans pathogenesis in murine pulmonary infection
by EM (16), we noted that yeast cell capsules were
significantly better preserved in lung tissue than when fixed in
aqueous cell suspension. Many experiments in our laboratory carried out
over several years had shown that capsule preservation is poor when
C. neoformans cells grown in vitro are embedded in plastic
(unpublished results). We considered the possibility that this
reflected capsule growth in vivo. Comparison of C. neoformans capsules in murine lung tissue at 5 min and 2 h
after infection revealed comparable appearance and size consistent with
preservation of the capsule structure by fixation in tissue.
Immunogold EM of MAb binding to C. neoformans.
When
C. neoformans cells in cut tissue sections were incubated
with either MAb 12A1, 13F1, or 2H1 followed by detection with a
gold-conjugated reagent, binding was noted throughout the capsule for
all MAbs (Fig. 1), implying similar
distributions of their epitopes. For each of these MAbs, the average
number of gold balls per square micrometer was highest in the region of
the capsule adjacent to the yeast cell wall and declined progressively
as a function of the radius of the distance from the cell wall (Fig. 2). The gold ball density was
significantly higher for the two IgM MAbs than for the IgG1 MAb (Fig.
2).

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 1.
EM localization of MAbs 2H1 (A), 12A1 (B), and 13F1 (C)
binding on C. neoformans cells in cut sections from a mouse
lung visualized by postsectioning staining with immunogold. The yeast
cell in panel A is in the extracellular space, whereas those in panels
B and C are inside macrophages. Bars represent 1 µm. Images are
representative of many micrographs obtained for each MAb.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
Radial density of epitope for MAbs 2H1, 12A1, and 13F1
in the capsule of C. neoformans as demonstrated by
immunogold labeling. The capsular polysaccharide in sections from
infected mice was labeled with primary MAb followed by gold-conjugated
secondary antibody, and the number of gold particles in 0.1 µm2 was determined in regions of the capsule at various
distances from the cell wall on micrographs printed at a magnification
of ×30,000. Numbers represent means, and error bars denote standard
deviations. The following numbers of measurements were made at each
distance: 0.0 to 0.33 µm, 28 for 2H1, 11 for 12A1, and 12 for 13F1;
0.33 to 0.66 µm, 28 for 2H1, 11 for 12A1, and 13 for 13F1; 0.68 to
0.99 µm, 25 for 2H1, 11 for 12A1, and 13 for 13F1; 0.99 to 1.32 µm,
23 for 2H1, 11 for 12A1, and 13 for 13F1, 1.32 to 1.66 µm, 19 for
2H1, 11 for 12A1, and 13 for 13F1; >1.66 µm, 11 for 2H1, 29 for
12A1, and 37 for 13F1. *, P < 0.05 by two-tailed
Student's t test for measurement relative to the density of
gold particles at 0.0 to 33 µm.
|
|
The observation that all three MAbs bound in similar manners to
C. neoformans cells in cut tissue sections using immunogold detection contrasted with differences in IF patterns (annular for 2H1
and 12A1 and punctate for 13F1). Since the polysaccharide capsule for
yeast cells in cut tissue sections is immobilized by embedding in
plastic, this result implied that the punctate pattern produced by MAb
13F1 in solution reflected aggregation of antibody-antigen complexes
when the capsule matrix was not fixed in place. To investigate this
possibility, C. neoformans cells were incubated with either
MAb 12A1 or 13F1 and then gold-labeled GAM-IgM, instilled into mice,
fixed within 2 h, and studied by EM. For MAb 12A1, a continuous
electron-dense outer layer was seen which presumably consists of
antigen-antibody complexes localized to the surface of the capsule. For
MAb 13F1, the pattern consisted of separated dense patches toward the
polysaccharide capsule surface (Fig. 3).
These patterns appear to be the EM equivalent of the annular and
punctate IF patterns described for MAbs 12A1 and 13F1, respectively. In
other experiments, C. neoformans was incubated with either
MAb 12A1 or 13F1 alone, instilled into mouse lungs, fixed within 2 h, and then stained with gold-labeled GAM-IgM. Again, an electron-dense
layer was observed near the surface of the capsule for MAb 12A1,
whereas MAb 13F1 binding produced separated dense patches also near the
capsule surface (not shown). Hence, immunogold staining confirmed the
presence of IgM in the surface electron-dense layer observed when cells
were preincubated with MAb 12A1 and the separated electron-dense
patches were observed under similar circumstances with MAb 13F1. The
intensity of immunogold staining was significantly reduced for those
experiments where C. neoformans preincubated in MAb was
instilled into mouse tracheas relative to studies that used cut
sections, possibly reflecting immunoglobulin degradation by host or
fungal proteases in vivo.

View larger version (184K):
[in this window]
[in a new window]
|
FIG. 3.
EM of C. neoformans cells preincubated with
MAb 12A1 (A and B) or 13F1 (C and D) after inoculation into mouse
lungs. Each arrow in panels A and B denotes electron-dense layer on the
outer surface of C. neoformans after MAb 12A1 binding;
arrows in panels C and D denote electron-dense deposits on the capsule
of C. neoformans after MAb 13F1 binding. The patterns of
electron-dense deposits were the same regardless of whether MAbs 12A1
and 13F1 were used alone or together with secondary GAM-IgM. Bars
represent 1 µm.
|
|
IF MAb binding studies.
Although the EM studies suggested that
the binding of MAbs 12A1 and 13F1 to the capsule of intact cells
produced the patterns corresponding to the annular and punctate IF
patterns, we explored the requirement for secondary antibodies for
production of these patterns. Specifically, we investigated whether the
secondary antibodies used in indirect IF studies mediated the
antigen-antibody aggregation in the capsular matrix that appeared as
annular and punctate binding by indirect IF. Direct IF using
Alexa-conjugated MAbs 12A1 and 13F1 revealed annular and punctate IF
patterns, respectively (Fig. 4b and c).
This result is consistent with the EM findings and implies that the
annular and punctate IF patterns are a consequence of the binding of
the primary IgM MAbs to the capsular polysaccharide, not to the
secondary antibody reagent.

View larger version (116K):
[in this window]
[in a new window]
|
FIG. 4.
Fluorescence patterns resulting from the binding of
Alexa-conjugated MAbs 2H1 (a), 12A1 (b), and 13F1 (c) to C. neoformans cells. Bar represent 10 µm. Right, IF; left, light
microscopy.
|
|
In contrast to MAbs 12A1 and 13F1, the localization of fluorescence for
MAb 2H1 on the capsule differed depending on whether direct or indirect
IF techniques were used (Fig. 5). Incubation of C. neoformans cells with MAb 2H1 conjugated to Alexa 546 produced a
homogenous fluorescence throughout the entirety of the capsule, whereas
addition of native MAb 2H1 followed by rhodamine- and fluorescein-conjugated secondary reagents produced fluorescence localized to the outer surface of the cell (Fig.
5). Since this observation implied that
antibody binding to the capsule could modify or block the binding of
secondary antibody, we investigated this possibility using combinations
of the two IgM MAbs (12A1 and 13F1) and the IgG1 (2H1) in experiments
where these MAbs were added sequentially using both conjugated and
native MAbs (Fig. 5). The combination of MAbs 2H1 and 12A1 and 2H1 and
13F1 represented pairs of antibodies that bind to the same and
different antigenic determinants, respectively (36). MAbs
12A1 and 13F1 have very similar apparent affinity for C. neoformans polysaccharide (22). MAb binding was
detected by use of anti-GXM MAbs directly conjugated to Alexa dye or
indirectly using isotype-specific F- and R-GAM reagents. The results
are summarized in Table 1.

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 5.
IgM and IgG binding as detected by IF for C. neoformans cells stained with various combinations of MAbs 2H1,
12A1, and 13F1. For all panels, the order of images is light
microscopy, fluorescein staining, rhodamine staining, and superposition
of the fluorescein and rhodamine images. Panel letters are
cross-referenced with conditions listed in Table 1. (a) MAb 12A1,
F-GAM-IgM, MAb 2H1, R-GAM-IgG1; (b) MAb 2H1, R-GAM-IgG1, MAb 12A1,
F-GAM-IgM; (c) MAb 12A1, MAb 2H1, F-GAM-IgM, R-GAM-IgG1; (d) MAb 2H1,
MAb 12A1, R-GAM-IgG1, F-GAM-IgM; (e) MAb 12A1-Alexa 488, MAb 2H1-Alexa
546; (f) MAb 2H1-Alexa 546, MAb 12A1-Alexa 488; (g) MAb 13F1, MAb 2H1,
F-GAM-IgM, MAb 2H1, R-GAM-IgG1; (h) MAb 2H1, R-GAM-IgG1, MAb 13F1,
F-GAM-IgM; (i) MAb 13F1, MAb 2H1, F-GAM-IgM, R-GAM-IgG1; (j) MAb 2H1,
MAb 13F1, F-GAM-IgM, R-GAM-IgG1; (k) MAb 13F1-Alexa 488, MAb 2H1-Alexa
546; (l) MAb 2H1-Alexa 546, MAb 13F1A1-Alexa 488. Yellow results from
the superposition of green and red color and denotes areas where both
MAbs are bound to the capsule. Rhodamine and Alexa 546 appear orange
when superimposed with either FITC- or Alexa 488-stained images. Each
arrow in panel f points to a bud which does not stain with MAb 2H1. Bar
represents 10 µm.
|
|
Combining MAb 2H1 with either IgM did not significantly affect the
localization of IgM fluorescence regardless of whether the IgG1 was
added first or second (Fig. 5; Table 1). However, the localization of
IgG1 fluorescence corresponding to MAb 2H1 binding in the C. neoformans capsule was altered by MAb 12A1, both when the IgG1 was
added first and when it was added second. Specifically, when studied by
direct IF in the presence of MAb 12A1, IgG1 fluorescence was observed
primarily in the inner aspects of the capsule but not on the region
bound by MAb 12A1, suggesting that MAb 12A1 competitively inhibited MAb
2H1 binding. Partial exclusion of IgG1 from the outer rim of the
capsule was seen by indirect IF when the IgM and its secondary
conjugated reagent were both added before the IgG1. Further, when MAb
2H1 was added first, followed by 12A1 and then the secondary reagents,
IgG1 binding was observed throughout the capsule, suggesting that
IgM-antigen complex binding by an anti-IgM could permit access to the
IgG1. The combination of MAb 2H1 and 13F1 also modified the location of
MAb 2H1 binding despite the fact that these MAbs bind different epitopes (22, 36). Remarkably, MAb 13F1 binding facilitated detection of MAb 2H1 binding throughout the capsule when IgG1 localization was detected by indirect IF (Fig. 5; Table 1). However, when directly labeled 13F1 and 2H1 MAbs were used in combination, the
IgG1-related fluorescence was punctate in the outer rim, indicating yet
another modification of MAb 2H1 binding by the IgM.
MAb 12A1 and 13F1 binding to C. neoformans cells from
infected tissue.
One potential explanation for the lack of
efficacy of MAb 13F1 in mouse protection studies (23) was
that the epitope recognized by this MAb is not expressed by C. neoformans during infection. To investigate this possibility, we
used IF to compare levels of MAb 12A1 and 13F1 binding to C. neoformans cells recovered from infected tissue and to cells from
in vitro cultures. MAbs 12A1 and 13F1 bound to C. neoformans
cells in lung homogenates with annular and punctate IF patterns,
respectively (Fig. 6). Yeast cells from
tissue had larger capsules, but the pattern of IF was qualitatively
similar to that observed using C. neoformans cells grown in
vitro.

View larger version (105K):
[in this window]
[in a new window]
|
FIG. 6.
India ink preparations (a and b) and indirect IF (c and
d) of representative C. neoformans isolate from lungs of
infected mice. Organ suspension was stained with 50 µg each of IgM
MAbs 13F1 (a) and 12A1 (b) per ml. Scale bar = 10 µm (applies to
both panels).
|
|
MAb binding to daughter and mother cells.
Analysis of MAb 12A1
binding to budding cells revealed comparable fluorescence intensities
for both parent and budding cells (Fig. 5e). However, the fluorescence
intensity of MAb 2H1 and 13F1 binding to C. neoformans
budding cells was significantly lower than the intensity of binding to
the mother cell (for 2H1, Fig. 5f; for 13F1, data not shown). This
phenomenon was most apparent for cells from logarithmically growing cultures.
 |
DISCUSSION |
The C. neoformans capsular structure is easily
disrupted during preparation for EM (1, 5, 13, 30). During
previous studies of C. neoformans pulmonary infection
(14), we noted that capsules were significantly better
preserved when fixed in lung tissue than in solution. Since the
C. neoformans capsule increases in size during infection
(21, 29) and because iron availability (37) and
carbon dioxide concentration (17) can affect capsule size,
we investigated whether the difference in appearance reflected capsule
growth in vivo. EM examination of C. neoformans cells at 5 min and 2 h revealed that the capsules were comparable in size and
appearance (data not shown), consistent with the view that the detailed
appearance of capsules noted in lung tissue reflected improved
preservation. The mechanism by which fixing C. neoformans
cells in tissue preserves the capsule is not understood. Tissue
embedding may preserve the capsule by slowing the rate of dehydration
or by retarding diffusion of the capsular polysaccharide away from the
cell. Alternatively, tissue substances such as complement
(14) or surfactant may bind to the capsule in the alveolar
space and protect it during fixation and dehydration. Similarly,
antibody or complement can protect the C. neoformans capsule
from the dehydration steps that precede scanning EM (9).
Another attraction of studying MAb binding to the capsule in tissue is
that this technique approximates the state of C. neoformans
cells at the time of experimental infection.
Immunogold EM of MAbs 12A1, 13F1, and 2H1 bound to sectioned capsule
fixed in lung tissue revealed similar patterns of gold particle
localization for all three antibodies. For all three MAbs, binding was
observed throughout the capsule, but the density of binding was higher
in the inner regions of the capsule. This effect was most pronounced
for MAb 2H1. The regional differences in MAb binding to the capsule may
reflect structural differences in the architecture of the capsule as a
function of distance from the cell wall or a higher epitope density in
the inner capsule due to closer packing of polysaccharide fibrils near
the cell wall (31). Alternatively, there may be a
concentration gradient in polysaccharide molecules as a function of
distance from the cell wall such that the capsule is less dense in the
outer regions. The density of gold balls was significantly higher for
MAbs 12A1 and 13F1 than for MAb 2H1. This may reflect the higher
avidity of IgM class antibodies as a result of their pentameric
structure or a higher sensitivity for the IgM by the secondary
reagents. On the basis of the immunogold EM study of MAb binding to cut sections, one might have expected similar binding patterns for each of
these MAbs by other techniques. However, other studies have shown
significant differences in the binding of MAbs 12A1 and 13F1 by IF
(23), scanning EM (9), and transmission EM (23) when the MAbs are bound to yeast cells in solution.
Presumably, these differences reflect the fact that the immunogold EM
study used sectioned C. neoformans cells immobilized in a
plastic support in a manner that would preclude aggregation of
antigen-antibody complexes by polyvalent IgM or secondary antibody
cross-linking after antibody binding. Furthermore, this method exposes
epitopes in the inner portion of the capsule and allows unencumbered
access to that epitope by the antibody reagent. The biological
significance of antibody binding to internal epitopes is uncertain.
The similarities in immunogold EM after MAb 12A1 and 13F1 binding to
C. neoformans in cut sections from tissue strongly suggested that the differences in IF observed for MAb binding in solution were a
consequence of the formation of antigen-antibody complexes in the
capsule matrix. To study this possibility, we investigated antibody
localization by EM after binding in solution of MAbs 12A1 and 13F1
alone, followed by a secondary gold-labeled polyclonal antibody to
mouse immunoglobulin. When MAbs 12A1 and 13F1 were added to C. neoformans in solution and the sample was then processed for EM,
we observed electron-dense deposits in the capsule with and without the
addition of GAM-IgM. The electron-dense deposits contained IgM and
appear to be the EM equivalents of the annular and punctate patterns
observed by IF. The only other study in the literature comparing
immunogold EM and IF of a MAb to C. neoformans also reported
comparable patterns when antibody was bound to cells in solution before
microscopy (35). Hence, immunogold EM and IF appear to
produce consistent antibody localization results when the EM samples
are prepared by reacting C. neoformans with the antibody in
solution before processing. The location of gold particles observed in
this study differs from an earlier study that evaluated MAb 12A1 and
13F1 binding to cells in solution (23). That study showed
MAb 12A1 binding primarily on the capsule surface and MAb 13F1 binding
primarily inside the capsule. We attribute these differences to the
different methodologies used and note that the presence of thick
polysaccharide fibrils in the earlier micrographs suggest a
preservation artifact.
When comparing antibody binding to C. neoformans in
vitro and in vivo, it is important to consider the possibility that
several variables could affect interpretation of the results. Alveolar spaces contain complement and surfactant components that may bind to
the capsule and could conceivably affect the amount and location of
antibody binding through steric and/or conformational effects. Although
some effect of these endogenous humoral components cannot be totally
excluded, we note that the antibody binding pattern (e.g., punctate and
annular) was consistent for C. neoformans grown in vitro and
recovered from lung homogenates. This suggests no interference in
antibody-antigen complex formation in the capsule from other humoral
substances in the binding of these MAbs. The possibility that
endogenous antibody influences the results is extremely unlikely since
this mouse strain does not make an appreciable antibody response
(14), and control experiments revealed no secondary antibody
binding to the capsule in the absence of primary MAb. Finally, tissue
embedding may model C. neoformans infection in organs like
the lung but may not accurately represent yeast cells in cerebrospinal
fluid and serum, which are also found during infection. Despite these
caveats, we believe that tissue embedding provides a new option for the
study of capsule structure and antibody binding reactions.
Although the EM localization experiments strongly suggested that the
different patterns were a property of the binding of primary IgM MAb to
the capsule, we considered the possibility that the secondary antibody
contributed to this effect by promoting the aggregation of primary
antibody-antigen complexes. However, IF binding studies performed in
solution using Alexa dye-labeled MAbs 12A1 and 13F1 revealed annular
and punctate patterns, respectively, indicating that the effect was not
due to antigen-antibody complex aggregation by the secondary antibody.
The observation that MAb 12A1 localized to the surface despite the
presence of its epitope throughout the capsule suggested that initial
antibody binding at the surface could interfere with penetration of
additional antibody to the deeper regions of the capsule. To
investigate this possibility, MAbs 12A1 and 2H1 were added sequentially
followed by secondary antibodies. In all combinations, MAb 12A1 bound
preferentially to the outer rim, whereas the location of the apparent
binding of MAb 2H1 was dependent on whether IgM was bound first and on the use of secondary reagents. Together, these results suggest that the
annular pattern observed with MAb 12A1 represents preferential binding
to the outer rim of the capsule. Whether this effect reflects a
conformational change in the capsule that alters permeability or
affinity is not known. We note that although several antibody combinations resulted in modification of the binding of subsequent primary or secondary antibody reagents, none of the antibodies tested
completely blocked the binding of subsequent antibodies.
Capsule binding by MAb 2H1 to the capsule rim was reduced by MAb 12A1
when evaluated by direct IF, consistent with the observation that these
two MAbs have similar, if not the same, epitope specificity (36) and that MAb 12A1 has higher affinity than MAb 2H1
(22). However, MAb 13F1 binding to the C. neoformans capsule also affected the binding of MAb 2H1 despite
the fact that these MAbs bind to different epitopes (25,
36). Most interesting was the fact that combinations of MAbs 2H1
and 13F1 using directly labeled antibody resulted in punctate patterns
of IgG localization at the capsule surface. Whether this reflects
increased affinity of MAb 2H1 for polysaccharide in the vicinity of MAb
13F1-antigen complexes or a negative staining visual effect is
uncertain. The variation in the pattern seen with the various antibody
combinations indicates that the binding of one antibody to the capsule
can modify the binding of antibodies of the same or different specificity.
Previous studies of C. neoformans cells grown in vitro
have shown that the capsule over budding cells is thinner than that of
the parent cell, indicating quantitative differences in the polysaccharide capsule of daughter and mother cells (5).
However, to our knowledge, no qualitative differences in the type of
polysaccharide capsule over daughter and mother cells have been
described. The intensity of MAb 2H1 and 13F1 binding to the buds of
replicating cells was significantly lower than for the mother cell. In
contrast, there was no significant difference in the staining of
daughter and mother cells by MAb 12A1. This observation suggests that
the polysaccharide capsule over the bud is different from that over the
mother cell. Since MAbs 12A1 and 2H1 are believed to bind to the same
epitope in GXM on the basis of fine specificity mapping using peptide
mimetics of GXM (36), this result could imply differences in
the avidity of the IgM and IgG1 for the bud polysaccharide. Differences
in avidity could arise if the pentameric IgM was more likely to form
strong binding sites with the bud capsule than the bivalent IgG1.
Alternatively, the differences in 12A1 and 2H1 binding for nascent buds
can indicate differences in specificity. The lower affinity of MAb 2H1
for newly formed buds suggests a mechanism by which the newly formed
offspring of replicating cells may escape the protective effects of IgG.
In summary, our results indicate that antibody binding to the C. neoformans capsule can modify the binding of subsequent antibodies to the polysaccharide antigen or to the primary antibody. In practical terms, this means that the pattern of antibody binding to the C. neoformans capsule can differ depending on whether direct or indirect IF techniques are used to visualize the location of antibody binding. The differences in IF pattern observed depending on the methodology used imply a need for caution when making conclusions regarding the location of antibody binding from studies that rely on
single methods. In contrast, the combination of EM and solution IF
studies can provide complementary information on the location of
binding to a microbial capsule. The multitude of localization patterns
obtained with just three MAbs depending on the reaction order and the
methodology used to detect bound antibody highlight the complexity of
antibody interactions with microbial capsules. One can anticipate
significantly higher complexity for antibody-capsule interactions in
vivo since antibody responses include antibodies of multiple
specificities and isotype.
 |
ACKNOWLEDGMENTS |
M.F. and J.R. contributed equally to this work.
M.F. is supported by NIH award KO8AI01341. J.R. is supported by MARC
predoctoral fellowship 5-F31-GM18951. T.R.K. is supported by grant
RO1-AI14209. A.C. is supported by NIH awards AI33774, AI3342, and
HL-59842-01 and a Burroughs Wellcome Development Therapeutics Award.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, 1300 Morris Park Ave., Bronx, NY 10461. Phone: (718)
430-4259. Fax: (718) 430-8968. E-mail:
casadeva{at}aecom.yu.edu.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Al-Doory, Y.
1971.
The ultrastructure of Cryptococcus neoformans.
Sabouraudia
9:113-118.
|
| 2.
|
Bolduan, C. F., and J. Koopman.
1917.
Immune sera, p. 67-134.
John Wiley & Sons, Inc., New York, N.Y.
|
| 3.
|
Casadevall, A.,
M. DeShaw,
M. Fan,
F. Dromer,
T. R. Kozel, and L. Pirofski.
1994.
Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
Infect. Immun.
62:3864-3872[Abstract/Free Full Text].
|
| 4.
|
Casadevall, A.,
J. Mukherjee,
S. J. N. Devi,
R. Schneerson,
J. B. Robbins, and M. D. Scharff.
1992.
Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
J. Infect. Dis.
65:1086-1093.
|
| 5.
|
Cassone, A.,
N. Simonetti, and V. Strippoli.
1974.
Wall structure and bud formation on Cryptococcus neoformans.
Arch. Microbiol.
95:205-212[CrossRef].
|
| 6.
|
Cherniak, R., and J. B. Sundstrom.
1994.
Polysaccharide antigens of the capsule of Cryptococcus neoformans.
Infect. Immun.
62:1507-1512[Abstract/Free Full Text].
|
| 7.
|
Cleare, W.,
M. E. Brandt, and A. Casadevall.
1999.
Monoclonal antibody 13F1 produces annular immunofluorescent patterns on Cryptococcus neoformans serotype AD isolates.
J. Clin. Microbiol.
37:3080[Free Full Text].
|
| 8.
|
Cleare, W., and A. Casadevall.
1998.
The different binding patterns of two IgM monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlates with serotype classification and differences in functional assays.
Clin. Diagn. Lab. Immunol.
5:125-129[Abstract/Free Full Text].
|
| 9.
|
Cleare, W., and A. Casadevall.
1999.
Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release.
Med. Mycol.
37:235-243[CrossRef][Medline].
|
| 10.
|
Dromer, F.,
S. Mathoulin,
B. Dupont, and A. Laporte.
1996.
Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993).
Clin. Infect. Dis.
23:82-90[Medline].
|
| 11.
|
Dromer, F.,
J. Salamero,
A. Contrepois,
C. Carbon, and P. Yeni.
1987.
Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.
Infect. Immun.
55:742-748[Abstract/Free Full Text].
|
| 12.
|
Eckert, T. F., and T. R. Kozel.
1987.
Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Infect. Immun.
55:1895-1899[Abstract/Free Full Text].
|
| 13.
|
Edwards, M. R.,
M. A. Gordon,
E. W. Lapa, and W. C. Ghiorse.
1967.
Micromorphology of Cryptococcus neoformans.
J. Bacteriol.
94:766-777[Abstract/Free Full Text].
|
| 14.
|
Feldmesser, M., and A. Casadevall.
1997.
Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans.
J. Immunol.
158:790-799[Abstract].
|
| 15.
|
Feldmesser, M., and A. Casadevall.
1998.
Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.
Front. Biosci.
3:136-151.
|
| 16.
|
Feldmesser, M.,
A. Casadevall,
Y. Kress,
G. Spira, and A. Orlofski.
1997.
Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro.
Infect. Immun.
65:1899-1907[Abstract].
|
| 17.
|
Granger, D. L.,
J. R. Perfect, and D. T. Durack.
1985.
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.
J. Clin. Investig.
76:508-516.
|
| 18.
|
Kozel, T. R.
1996.
Activation of the complement system by pathogenic fungi.
Clin. Microbiol. Rev.
9:34-46[Abstract].
|
| 19.
|
Kozel, T. R.,
B. C. H. deJong,
M. M. Grinsell,
R. S. MacGill, and K. K. Wall.
1998.
Characterization of anti-capsular monoclonal antibodies that regulate activation of the complement system by Cryptococcus neoformans.
Infect. Immun.
66:1538-1546[Abstract/Free Full Text].
|
| 20.
|
Levitz, S. M.,
D. J. DiBenedetto, and R. D. Diamond.
1987.
A rapid fluorescent assay to distinguish attached from phagocytized yeast particles.
J. Immunol. Methods
101:37-42[CrossRef][Medline].
|
| 21.
|
Littman, M. L.
1958.
Capsule synthesis by Cryptococcus neoformans.
Trans. N. Y. Acad. Sci.
20:623-648[Medline].
|
| 22.
|
Mukherjee, J.,
A. Casadevall, and M. D. Scharff.
1993.
Molecular characterization of the antibody responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.
J. Exp. Med.
177:1105-1106[Abstract/Free Full Text].
|
| 23.
|
Mukherjee, J.,
G. Nussbaum,
M. D. Scharff, and A. Casadevall.
1995.
Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell.
J. Exp. Med.
181:405-409[Abstract/Free Full Text].
|
| 24.
|
Mukherjee, S.,
M. Feldmesser, and A. Casadevall.
1996.
J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins.
J. Infect. Dis.
173:1222-1231[Medline].
|
| 25.
|
Nussbaum, G.,
W. Cleare,
A. Casadevall,
M. D. Scharff, and P. Valadon.
1997.
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.
J. Exp. Med.
185:685-697[Abstract/Free Full Text].
|
| 26.
|
Pirofski, L., and A. Casadevall.
1996.
Antibody immunity to Cryptococcus neoformans: paradigm for antibody immunity to the fungi?
Zentbl. Bakteriol.
284:475-495.
|
| 27.
|
Pirofski, L.,
R. Lui,
M. DeShaw,
A. B. Kressel, and Z. Zhong.
1995.
Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Infect. Immun.
63:3005-3014[Abstract].
|
| 28.
|
Rhodes, J. C.,
L. S. Wicker, and W. Urba.
1980.
Genetic control of susceptibility to Cryptococcus neoformans in mice.
Infect. Immun.
29:494-499[Abstract/Free Full Text].
|
| 29.
|
Rivera, J.,
M. Feldmesser,
M. Cammer, and A. Casadevall.
1998.
Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection.
Infect. Immun.
66:5027-5030[Abstract/Free Full Text].
|
| 30.
|
Sakaguchi, N.
1993.
Ultrastructural study of hepatic granulomas induced by Cryptococcus neoformans by quick-freezing and deep-etching method.
Virchows Arch. B Cell Pathol.
64:57-66[Medline].
|
| 31.
|
Sakaguchi, N.,
T. Baba,
M. Fukuzawa, and S. Ohno.
1993.
Ultrastructural study of Cryptococcus neoformans by quick-freezing and deep-etching method.
Mycopathologia
121:133-141[CrossRef][Medline].
|
| 32.
|
Schlagetter, A. M., and T. R. Kozel.
1990.
Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.
Infect. Immun.
58:1914-1918[Abstract/Free Full Text].
|
| 33.
|
Syme, R. M.,
T. F. Bruno,
T. R. Kozel, and C. H. Mody.
1999.
The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody.
Infect. Immun.
67:4620-4627[Abstract/Free Full Text].
|
| 34.
|
Todaro-Luck, F.,
E. Reiss,
R. Cherniak, and L. Kaufman.
1989.
Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Infect. Immun.
57:3882-3887[Abstract/Free Full Text].
|
| 35.
|
Todaro-Luck, F.,
E. H. White,
E. Reiss, and R. Cherniak.
1989.
Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Mol. Cell. Probes
3:345-361[CrossRef][Medline].
|
| 36.
|
Valadon, P.,
G. Nussbaum,
L. F. Boyd,
D. H. Margulies, and M. D. Scharff.
1996.
Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
J. Mol. Biol.
261:11-22[CrossRef][Medline].
|
| 37.
|
Vartivarian, S. E.,
E. J. Anaissie,
R. E. Cowart,
H. A. Sprigg,
M. J. Tingler, and E. S. Jacobson.
1993.
Regulation of cryptococcal capsular polysaccharide by iron.
J. Infect. Dis.
167:186-190[Medline].
|
| 38.
|
Vecchiarelli, A., and A. Casadevall.
1998.
Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity.
Res. Immunol.
149:321-333[CrossRef][Medline].
|
| 39.
|
Vecchiarelli, A.,
C. Retini,
C. Monari, and A. Casadevall.
1998.
Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation.
Infect. Immun.
66:1244-1247[Abstract/Free Full Text].
|
Infection and Immunity, June 2000, p. 3642-3650, Vol. 68, No. 6
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mandal, P., Banerjee, U., Casadevall, A., Nosanchuk, J. D.
(2005). Dual Infections with Pigmented and Albino Strains of Cryptococcus neoformans in Patients with or without Human Immunodeficiency Virus Infection in India. J. Clin. Microbiol.
43: 4766-4772
[Abstract]
[Full Text]
-
Fries, B. C., Lee, S. C., Kennan, R., Zhao, W., Casadevall, A., Goldman, D. L.
(2005). Phenotypic Switching of Cryptococcus neoformans Can Produce Variants That Elicit Increased Intracranial Pressure in a Rat Model of Cryptococcal Meningoencephalitis. Infect. Immun.
73: 1779-1787
[Abstract]
[Full Text]
-
Torres, M., May, R., Scharff, M. D., Casadevall, A.
(2005). Variable-Region-Identical Antibodies Differing in Isotype Demonstrate Differences in Fine Specificity and Idiotype. J. Immunol.
174: 2132-2142
[Abstract]
[Full Text]
-
Martinez, L. R., Moussai, D., Casadevall, A.
(2004). Antibody to Cryptococcus neoformans Glucuronoxylomannan Inhibits the Release of Capsular Antigen. Infect. Immun.
72: 3674-3679
[Abstract]
[Full Text]
-
Apidianakis, Y., Rahme, L. G., Heitman, J., Ausubel, F. M., Calderwood, S. B., Mylonakis, E.
(2004). Challenge of Drosophila melanogaster with Cryptococcus neoformans and Role of the Innate Immune Response. Eukaryot Cell
3: 413-419
[Abstract]
[Full Text]
-
Sommer, U., Liu, H., Doering, T. L.
(2003). An {alpha}-1,3-Mannosyltransferase of Cryptococcus neoformans. J. Biol. Chem.
278: 47724-47730
[Abstract]
[Full Text]
-
Nosanchuk, J. D., Casadevall, A.
(2003). Budding of melanized Cryptococcus neoformans in the presence or absence of L-dopa. Microbiology
149: 1945-1951
[Abstract]
[Full Text]
-
Mylonakis, E., Ausubel, F. M., Perfect, J. R., Heitman, J., Calderwood, S. B.
(2002). Killing of Caenorhabditiselegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc. Natl. Acad. Sci. USA
99: 15675-15680
[Abstract]
[Full Text]
-
McLean, G. R., Torres, M., Elguezabal, N., Nakouzi, A., Casadevall, A.
(2002). Isotype Can Affect the Fine Specificity of an Antibody for a Polysaccharide Antigen. J. Immunol.
169: 1379-1386
[Abstract]
[Full Text]
-
Feldmesser, M., Kress, Y., Casadevall, A.
(2001). Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology
147: 2355-2365
[Abstract]
[Full Text]
-
Nakouzi, A., Valadon, P., Nosanchuk, J., Green, N., Casadevall, A.
(2001). Molecular Basis for Immunoglobulin M Specificity to Epitopes in Cryptococcus neoformans Polysaccharide That Elicit Protective and Nonprotective Antibodies. Infect. Immun.
69: 3398-3409
[Abstract]
[Full Text]
-
Taborda, C. P., Casadevall, A.
(2001). Immunoglobulin M Efficacy Against Cryptococcus neoformans: Mechanism, Dose Dependence, and Prozone-Like Effects in Passive Protection Experiments. J. Immunol.
166: 2100-2107
[Abstract]
[Full Text]
-
Rodrigues, M. L., Travassos, L. R., Miranda, K. R., Franzen, A. J., Rozental, S., de Souza, W., Alviano, C. S., Barreto-Bergter, E.
(2000). Human Antibodies against a Purified Glucosylceramide from Cryptococcus neoformans Inhibit Cell Budding and Fungal Growth. Infect. Immun.
68: 7049-7060
[Abstract]
[Full Text]
-
Mambula, S. S., Simons, E. R., Hastey, R., Selsted, M. E., Levitz, S. M.
(2000). Human Neutrophil-Mediated Nonoxidative Antifungal Activity against Cryptococcus neoformans. Infect. Immun.
68: 6257-6264
[Abstract]
[Full Text]